STEM CELL GROUP
A new group of stem cell research was recently established at the KG Jebsen Center for Diabetes Research.
As described below, the Stem Cell Group was recently established within the KGJ Center in order to address new possibilities emerging from the use of induced pluripotent stem cells (iPSC) in personalized medicine.
The group’s main recent research achievement has been the successful making of human iPSCs from fibroblasts from several members in families with MODY1, 2, 3, 5 and 8 (Teo et al., 2013, J Biological Chemistry). Moreover, we have been using proteomics to define the pancreatic secretome in MODY8 patients (Ræder et al., Diabetes, 2014).
Thus, during the first two years of the funding period, we have been able to publish papers in top journals in general medicine (JAMA, Science Translational Medicine), genetics (2 in Nature Genetics; American J Human Genetics), cell biology (Cell), diabetes and endocrinology (Diabetes), and biochemistry (3 in J Biological Chemistry). Moreover, we have written a review in Nature Reviews Endocrinology. In all these papers, we are either the primary research group or we significantly contribute experimentally. Thus, our contributions always stretch well beyond the delivery of patient samples.
Head of group: Helge Ræder
Read more about this groups activities on the Raederlab BLOG.
- Rohit Kulkarni, Joslin Diabetes Center, Boston, US
- Marco Metzger, Frauenhofer Institute, Wurzburg, Germany
- Beate Heissig, Tokyo University, Japan
- Adrian Teo, NTU, Singapore
- Pedro Herrera, Univeristy of Geneva, Switzerland
- Hanne Scholz, UiOBerit Strand, NTNU
Stem cell lab in BUS1, 6. floor,Haukelandsbakken 15, 5021 Bergen, Norway
- Stem cell lab with Amaxa Nucleofector for electroporation
- QIAxcel Advanced System